HeyJaredASCO Guidelines
Explore pivotal recommendations from the latest evidence-based clinical practice guidance with ASCO Guidelines. Join us to discover essential insights and navigate the ever-evolving landscape of cancer research and treatment.
- Indexed episodes, last 90 days
- 3
- Latest publication
- Aug 26, 2026
- Audience
- Checking…
- Earliest in this view
- Jul 28, 2026
Latest episodes
Breast Cancer Follow-Up and Surveillance After Primary Treatment Guideline Update (opens the original)
Read excerpt
Drs. Zeina Nahleh and Maryam Lustberg join the podcast to discuss the updated ASCO guideline on breast cancer follow-up and surveillance after primary treatment. Drs. Nahleh and Lustberg explain the new risk-stratified approach, which personalizes surveillance intensity based on a patient's risk of recurrence, moving away from a one-size-fits-all model. They detail the recommendations for low, intermediate, and high-intensity surveillance groups, review the current role of blood-based biomarkers
Systemic Treatment of Ovarian Cancer Recurrence: ASCO Living Guideline 2026.1.0 (opens the original)
Read excerpt
Drs. Jamie Lesnock and Sara Bouberhan join the podcast to discuss the first ASCO guideline on systemic treatment for recurrent ovarian cancer. They provide a comprehensive overview of the evidence-based recommendations for patients with both platinum-sensitive and platinum-resistant or platinum-refractory disease. The discussion covers systemic therapy options, the role of maintenance therapy with agents like bevacizumab, and the nuanced recommendations for secondary cytoreductive surgery based
Therapy for Stage IV NSCLC With Driver Alterations: ASCO Living Guideline Update 2026.3.2 (opens the original)
Read excerpt
Dr. Sonam Puri joins the podcast to share the update to the living guideline on stage IV NSCLC with driver alterations. Dr. Puri discusses the practice-changing evidence reviewed for both NTRK rearrangements, including the TRIDENT-1 trial, and HER2 activating mutations, including the Beamion LUNG-1 study. She shares how these results impacted the clinical practice guideline with the addition of repotrectinib and zongertinib, what these new TKIs mean for patients, and where the panel is waiting f
Publishing over time
Last 90 days. Choose a month to open its work.
Recurring subjects
Named in the text we hold. One piece can cover several.
Audience
No verified audience measurement yet.
About this data
Counts cover the work we have indexed. Tone needs enough text and a confident classification. Excerpts and episode notes are not full articles or transcripts.
Identity or attribution wrong? Suggest a correction.